東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Linked to FindBook

Google Book

Amazon

博客來

Pre-Clinical Development of Vitamin B12 Photoactivatable Therapeutics.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Pre-Clinical Development of Vitamin B12 Photoactivatable Therapeutics./
Author:	Zywot, Emilia M.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	355 p.
Notes:	Source: Dissertations Abstracts International, Volume: 83-03, Section: B.
Contained By:	Dissertations Abstracts International83-03B.
Subject:	Pharmaceutical sciences. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28650334
ISBN:	9798538122639

Pre-Clinical Development of Vitamin B12 Photoactivatable Therapeutics.
Zywot, Emilia M.

Pre-Clinical Development of Vitamin B12 Photoactivatable Therapeutics. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 355 p.

Source: Dissertations Abstracts International, Volume: 83-03, Section: B.

Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2021.

This item must not be sold to any third party vendors.

Photoactivatable therapeutics are targeted light-activated drug delivery systems composed of a therapeutic cargo appended to a photoresponsive moiety, which releases the cargo upon illumination. These targeted therapeutics have the potential to diminish toxicity and improve efficacy of the therapeutic cargo due to the temporal and spatial control provided by external light controlled therapeutic release. The introduction of this dissertation describes the precedent set by clinically approved photodynamic therapy and currently available photoresponsive moieties. Together, this background contributes to the proposed pre-clinical development plan for photoactivatable therapeutics.Vitamin B12, or cobalamin (Cbl), has shown exciting potential as a photoresponsive moiety with inherent photoresponsivity and minimal toxicity. Herein, two Cbl-based photoactivatable therapeutics encapsulated in red blood cells (RBCs) are developed. In vivo studies of a Cbl RBC chemotherapeutic and anti-inflammatory drug demonstrate localized delivery and efficacy comparable to standard of care respectively. Together, the advances contribute to the pre-clinical development plan for Cy5-Cbl photoactivatable therapeutics proposed in the conclusion. Overall, photoactivatable therapeutics, and Cy5-Cbl therapies specifically, are not far from first in human trials.

ISBN: 9798538122639Subjects--Topical Terms:

3173021
Pharmaceutical sciences.
Subjects--Index Terms:

Drug Delivery System

Pre-Clinical Development of Vitamin B12 Photoactivatable Therapeutics.
LDR:02629nmm a2200409 4500 001 2347499
005 20220801062218.5
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798538122639
035 $a (MiAaPQ)AAI28650334
035 $a AAI28650334
040 $a MiAaPQ $c MiAaPQ
100 1 $a Zywot, Emilia M. $3 3686761
245 1 0 $a Pre-Clinical Development of Vitamin B12 Photoactivatable Therapeutics.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 355 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-03, Section: B.
500 $a Advisor: Lawrence, David S.
502 $a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Photoactivatable therapeutics are targeted light-activated drug delivery systems composed of a therapeutic cargo appended to a photoresponsive moiety, which releases the cargo upon illumination. These targeted therapeutics have the potential to diminish toxicity and improve efficacy of the therapeutic cargo due to the temporal and spatial control provided by external light controlled therapeutic release. The introduction of this dissertation describes the precedent set by clinically approved photodynamic therapy and currently available photoresponsive moieties. Together, this background contributes to the proposed pre-clinical development plan for photoactivatable therapeutics.Vitamin B12, or cobalamin (Cbl), has shown exciting potential as a photoresponsive moiety with inherent photoresponsivity and minimal toxicity. Herein, two Cbl-based photoactivatable therapeutics encapsulated in red blood cells (RBCs) are developed. In vivo studies of a Cbl RBC chemotherapeutic and anti-inflammatory drug demonstrate localized delivery and efficacy comparable to standard of care respectively. Together, the advances contribute to the pre-clinical development plan for Cy5-Cbl photoactivatable therapeutics proposed in the conclusion. Overall, photoactivatable therapeutics, and Cy5-Cbl therapies specifically, are not far from first in human trials.
590 $a School code: 0153.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Cellular biology. $3 3172791
650 4 $a Pharmacology. $3 634543
650 4 $a Biomedical engineering. $3 535387
650 4 $a Molecular biology. $3 517296
653 $a Drug Delivery System
653 $a Light-Activated
653 $a Non-Clinical Drug Development
653 $a Photoactivated Therapy
653 $a Red Blood Cells
653 $a Vitamin B12
690 $a 0572
690 $a 0379
690 $a 0541
690 $a 0419
690 $a 0307
710 2 $a The University of North Carolina at Chapel Hill. $b Pharmaceutical Sciences. $3 1285238
773 0 $t Dissertations Abstracts International $g 83-03B.
790 $a 0153
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28650334